Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HINT1 | P49773 | 2/20 | 0.51 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9200583 | 1.00 | ADORA3 (0.53) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL16695880 | 1.00 | ADORA3 (0.53) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL11929887 | 1.00 | ADORA3 (0.53) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL98906 | 1.00 | ADORA3 (0.53) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL4323450 | 1.00 | ADORA3 (0.53) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL13833321 | 1.00 | ADORA3 (0.53) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL18759056 | 1.00 | ADORA3 (0.53) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL12031117 | 1.00 | ADORA3 (0.53) | ADORA3STING1PDE3BPDE3AHPGD | |
| Phosphoric Acid SCHEMBL16213328 | 0.96 | NT5E (0.54) | ADORA3STING1PDE3BPDE3AHPGD | |
| SCHEMBL23633225 | 0.92 | ADORA3 (0.51) | ADORA3STING1PDE3BPDE3AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 920 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4733408-A2 | METHODS TO MINIMIZE BARCODE EXCHANGE | 10X Genomics, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-12473557-B2 | Engineered guanylate kinase variant enzymes | CODEXIS, INC. (US) | 2025-11-18 | — | — | US | claimed |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| US-20250170228-A1 | TERMINALLY MODIFIED RNA | ARES CAPITAL CORPORATION, AS AGENT | 2025-05-29 | — | — | US | claimed |
| US-20250011859-A1 | COMPOSITIONS AND METHODS FOR END TO END CAPTURE OF MESSENGER RNAS | THE BROAD INSTITUTE, INC. (US) | 2025-01-09 | — | — | US | claimed |
| US-20240425940-A1 | COMPOSITIONS AND METHODS FOR ISOTHERMAL AMPLIFICATION OF NUCLEIC ACIDS | SIRO DIAGNOSTICS, INC. | 2024-12-26 | — | — | US | claimed |
| US-12163179-B2 | Methods and systems to minimize barcode exchange | 10X GEMOMICS, INC. (US) | 2024-12-10 | — | — | US | claimed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | claimed |
| EP-4312942-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) | 2003-01-09 | — | — | US | claimed |
| WO-2002018404-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | claimed |
| US-20020019363-A1 | Method for the treatment or prevention of flavivirus infections using nucleoside analogues | VIROCHEM PHARMA INC. (CA) | 2002-02-14 | — | — | US | claimed |
| EP-0090417-B1 | PROCESS FOR PRODUCING 3'-DEOXYGUANOSINE | Yamasa Shoyu Kabushiki Kaisha (JP) | 1989-03-01 | — | — | EP | claimed |
| US-4594321-A | Reacting guanine derivative with phosphate | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1986-06-10 | — | — | US | claimed |
| US-4594320-A | Reacting guanine derivative with phosphate compound | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1986-06-10 | — | — | US | claimed |
| US-4434788-A | 3'-DEOXYGUANOSINE OR 3'-DEOXYURIDINE ADMINISTERED WITH RADIATION | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1984-03-06 | — | — | US | claimed |
| EP-0090417-A2 | Process for producing 3'-deoxyguanosine | Yamasa Shoyu Kabushiki Kaisha (JP) | 1983-10-05 | — | — | EP | claimed |
| EP-0045944-B1 | ENHANCER OF ANTI-TUMOR EFFECT | Yamasa Shoyu Kabushiki Kaisha (JP) | 1983-08-31 | — | — | EP | claimed |
| EP-0045944-A1 | Enhancer of anti-tumor effect | Yamasa Shoyu Kabushiki Kaisha (JP) | 1982-02-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019363-A1 | Method for the treatment or prevention of flavivirus infections using nucleoside analogues | NUDT1, HAVCR2, SLC28A1 | ADORA3 1034/4885STING1 59/4885PDE3B 629/4885 |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | ADORA3 102/4885STING1 84/4885PDE3B 777/4885 |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | ADORA3 558/4885STING1 2225/4885PDE3B 4771/4885 |
| US-20250170228-A1 | TERMINALLY MODIFIED RNA | RNGTT, NSUN3, RNMT | ADORA3 2884/4885STING1 660/4885PDE3B 3518/4885 |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | ADORA3 4335/4885STING1 188/4885PDE3B 3393/4885 |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | SLC10A1, HAVCR2, HDGF | ADORA3 3777/4885STING1 2314/4885PDE3B 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.